Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

ClinicalTrials.gov ID: NCT07218926

Public ClinicalTrials.gov record NCT07218926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) Versus Sunitinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.

Study identification

NCT ID
NCT07218926
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
450 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2, 2025
Primary completion
May 29, 2028
Completion
Nov 28, 2030
Last update posted
Sep 7, 2026

2025 – 2030

United States locations

U.S. sites
48
U.S. states
28
U.S. cities
44
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85054 Recruiting
GSK Investigational Site Duarte California 91010 Recruiting
GSK Investigational Site La Jolla California 92093 Recruiting
GSK Investigational Site Los Angeles California 90048 Recruiting
GSK Investigational Site San Francisco California 94158 Recruiting
GSK Investigational Site Upland California 91786 Recruiting
GSK Investigational Site Aurora Colorado 80045-2517 Recruiting
GSK Investigational Site New Haven Connecticut 06520 Recruiting
GSK Investigational Site Washington D.C. District of Columbia 20016 Recruiting
GSK Investigational Site Jacksonville Florida 41076 Recruiting
GSK Investigational Site Miami Florida 33136 Recruiting
GSK Investigational Site Orlando Florida 32806 Recruiting
GSK Investigational Site Tampa Florida 33612 Recruiting
GSK Investigational Site Chicago Illinois 60611 Recruiting
GSK Investigational Site Chicago Illinois 60637 Recruiting
GSK Investigational Site Iowa City Iowa 52242 Recruiting
GSK Investigational Site Overland Park Kansas 66210 Recruiting
GSK Investigational Site Baton Rouge Louisiana 70808 Recruiting
GSK Investigational Site Baltimore Maryland 21287 Recruiting
GSK Investigational Site Boston Massachusetts 02114-2696 Recruiting
GSK Investigational Site Boston Massachusetts 02215 Recruiting
GSK Investigational Site Ann Arbor Michigan 48109 Recruiting
GSK Investigational Site Rochester Minnesota 55905 Recruiting
GSK Investigational Site St Louis Missouri 63108 Recruiting
GSK Investigational Site Omaha Nebraska 68130-2042 Recruiting
GSK Investigational Site New Hyde Park New York 11042-1118 Recruiting
GSK Investigational Site New York New York 10032-3747 Recruiting
GSK Investigational Site New York New York 10065-6007 Recruiting
GSK Investigational Site Rochester New York 14642 Recruiting
GSK Investigational Site Charlotte North Carolina 28204 Recruiting
GSK Investigational Site Durham North Carolina 27710 Recruiting
GSK Investigational Site Canton Ohio 44718 Recruiting
GSK Investigational Site Columbus Ohio 43210 Recruiting
GSK Investigational Site Portland Oregon 97239-3011 Recruiting
GSK Investigational Site Philadelphia Pennsylvania 19106 Recruiting
GSK Investigational Site Philadelphia Pennsylvania 19111 Recruiting
GSK Investigational Site Pittsburgh Pennsylvania 15232 Recruiting
GSK Investigational Site Spartanburg South Carolina 29307 Recruiting
GSK Investigational Site Knoxville Tennessee 37920 Recruiting
GSK Investigational Site Dallas Texas 75246 Recruiting
GSK Investigational Site Houston Texas 77030 Recruiting
GSK Investigational Site Santa Monica Texas 90404 Recruiting
GSK Investigational Site Salt Lake City Utah 84106 Recruiting
GSK Investigational Site Charlottesville Virginia 22908-0817 Recruiting
GSK Investigational Site Fairfax Virginia 22031 Recruiting
GSK Investigational Site Seattle Washington 98109 Recruiting
GSK Investigational Site Tacoma Washington 98405 Recruiting
GSK Investigational Site Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07218926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 7, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07218926 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →